Oramed Pharmaceuticals (NASDAQ:ORMP) has received an official notification of granting patent right for the company’s patent for its invention titled, “Methods and Compositions for Oral Administrations of Proteins” by the State Intellectual Property Office of the People’s Republic of China.
The patent addresses Oramed’s platform technology, which underlies its products, including ORMD-0801, an orally ingestible insulin capsule.
